

INVO Bioscience Forms Scientific Advisory Board with Leaders from Fertility Industry

SARASOTA, Fla., Nov. 18, 2020 — **INVO Bioscience, Inc. (Nasdaq: INVO)** developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced the formation of its Scientific Advisory Board (SAB) with the appointment of several prominent members of the fertility industry, including:



- Tony Anderson, DHSc, ELD, multi-site laboratory director for Aspire Fertility as well as the founder of EmbryoDirector IVF Academy USA;
- Amber Cooper, MD, MSCI, FACOG, a reproductive endocrinologist and medical director of Vios Fertility Institute St. Louis;
- Karen R. Hammond, DNP, CRNP, IVF Program Director of the America Institute of Reproductive Medicine in Birmingham, Alabama; and
- Francisco “Paco” Arredondo, MD, MPH, FACOG, recently Chief Medical Officer of the United States largest network of fertility centers, overseeing more than 50 fertility specialists, and currently a partner in a joint venture developing INVOcell clinics in Mexico.

Drs. Anderson, Cooper, Hammond and Arredondo, will bring real-world experience working with INVOcell, and expertise across the fertility industry in general, advising and guiding INVO Bioscience as the company expands commercialization in the U.S. and across the world.

“We are pleased to launch our Scientific Advisory Board with a group of highly accomplished and respected physicians across the fertility industry,” commented Steve Shum, CEO of INVO Bioscience. “Their expertise and guidance will be invaluable as we continue to advance our commercialization efforts of INVOcell through the implementation of best practices across operational, educational and technical functions.”

Tony Anderson, DHSc, ELD is a multi-site laboratory director for Aspire Fertility as well as the founder of EmbryoDirector IVF Academy USA. Anderson started his career in the bovine laboratory in 1990 at Granada Biosciences and made it to the human laboratory in 1992 at IVF America in Livingston New Jersey. Dr. Anderson moved to North Carolina to work at Presbyterian Hospital under the direction of Dr. Klaus Wiemer in 1992. In 2009 Tony took on the challenge of a new start up in San Antonio at RMAX that has grown to 2 IVF centers and 2 satellite centers. Dr. Anderson has been an early adopter in blastocyst embryo transfer,

cryopreservation and pioneered blastocyst biopsy with and without laser technology for genetic testing.

Dr. Anderson completed his undergraduate studies at Oklahoma State University in Animal Science and Masters in Clinical Embryology studies at Leeds University under the direction of Professors Alan Handyside and Helen Picton. These studies focused on cryopreservation and non-invasive methods of predicting euploidy in early embryos. Tony completed his doctoral studies at a Nova Southeastern University, a private university in South Florida. These doctoral studies focused on the comparison of cryopreservation methods of oocytes as well as pre-implantation genetic testing (PGT) of embryos for optimized outcomes.

Amber R. Cooper, MD, MSCI, FACOG is a reproductive endocrinologist and medical director of Vios Fertility Institute St. Louis. She is board certified in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility and completed both her residency and fellowship at Washington University in St. Louis. She has helped thousands of patients with complex cases achieve successful outcomes, preserve fertility and fulfill the dream of parenthood.

During her years of practice, Dr. Cooper has received numerous awards for her outstanding surgical techniques, teaching excellence, clinical research and patient satisfaction, and has been named one of the Best Doctors in America by St. Louis Magazine for the last eight years running. She considers it her life's work to educate, empower, and improve care for those with infertility.

Dr. Cooper has authored articles for several medical journals and textbooks, led clinical studies, and has had her research covered in the local and national press. Most recently, she coauthored a multicenter publication on INVOcell use in the US. She speaks nationally and internationally on how cancer and autoimmune disease therapies affect reproductive health and fertility, ovarian aging, primary ovarian insufficiency and genetics. While she is passionate for all facets of fertility health, she has a special interest in improving IVF success and outcomes, fertility preservation, ovarian dysfunction, ovarian reserve and aging, hysteroscopic surgery, genetics and the environmental impact on ovarian aging and function.

Karen R. Hammond, DNP, CRNP is a board-certified Nurse Practitioner, is IVF Program Director at AIRM. A native of Birmingham, she earned her three degrees from the UAB and has practiced in reproductive endocrinology since 1985.

A recognized leader in reproductive endocrinology and infertility, she has been lectured at countless local, state, national, and international nursing and medical meetings; has received numerous awards for clinical, research, and professional service; and has published extensively in clinical literature.

In 2018, Dr Hammond established a unique *Affordable IVF* program that increases access to care for patients needing advanced fertility treatment that has drawn patients to her practice

from across the country who have deemed her *Fertility Fairy Godmother*.

Francisco Arredondo MD, MPH, FACOG graduated summa cum laude from the Monterrey Institute of Technology and Higher Studies School of Medicine in Mexico. In 1991, the Mexican president honored him as “one of the best medical students in the country.” Two years before that, Dr. Arredondo found his passion in fertility while collaborating with Mexico’s first successful In Vitro Fertilization team. His determination to become a fertility specialist led him to do: research at the World Health Organization’s Reproductive Biology Center in Mexico City; an internship in Kahn Mount Sinai School of Medicine in New York City; an OBGYN residency at University of Texas Health Science Center of San Antonio, Texas; a Fertility Fellowship at Hospital of the University of Pennsylvania; and a Master’s in Public Health at Harvard University where he focused on international health and business management. He practiced as an OBGYN in rural Kentucky and later became an Assistant Professor of Reproductive Biology at Case Western Reserve University in Cleveland, Ohio. Dr. Arredondo’s 40th birthday inspired him to combine his medical, entrepreneurial, and management skills to follow a new path as a “MedikalPreneur” – a term he coined – which led him back to San Antonio to open his own fertility center. Over 13 years, he and his three-member team grew a network of fertility centers and entrepreneurial ventures with more than 80 team members. In 2018 and 2019, some of his corporations underwent two mergers and made him the Chief Medical Officer of America’s largest network of fertility centers, overseeing more than 50 fertility specialists. After achieving his professional and financial goals, Dr. Arredondo sold his interest in many of his companies and embarked on a new venture: Social Entrepreneurship to democratize fertility services. A member of the medical advisory board for various American companies, he also advises national and international private equity firms that focus on health investments. Dr. Arredondo shares his success secrets so you can become a MedikalPreneur to transform your medical practice, achieve your greatest professional fulfillment, and maximize your financial potential

About INVO Bioscience

INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO”) is an innovative medical device company developing solutions for the global infertility industry. INVO’s goal is to increase access to care and expand fertility treatment across the globe while seeking to lower the cost and increase the availability of care. INVO’s lead commercial product, the INVOcell, is a patented Assisted Reproductive Technology (ART) used in the treatment of infertility. The INVOcell device and procedure is unique as the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development. As an alternative to traditional in Vitro Fertilization (IVF), the revolutionary in vivo method of vaginal incubation offers patients a more natural and intimate experience. INVO Bioscience is headquartered in Sarasota, FL. For more information, please visit <http://invobioscience.com/>

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at **www.sec.gov**. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

 View original content to download

multimedia:<http://www.prnewswire.com/news-releases/invo-bioscience-forms-scientific-advisory-board-with-leaders-from-fertility-industry-301175530.html>

SOURCE INVO Bioscience, Inc.